Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RANI
stocks logo

RANI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.067
-75.31%
--
--
-0.140
-36.36%
--
--
-0.160
-11.11%
Estimates Revision
The market is revising Upward the revenue expectations for Rani Therapeutics Holdings, Inc. (RANI) for FY2025, with the revenue forecasts being adjusted by 2759.98% over the past three months. During the same period, the stock price has changed by 212.62%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2759.98%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-19.14%
In Past 3 Month
Stock Price
Go Up
up Image
+212.62%
In Past 3 Month
Wall Street analysts forecast RANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RANI is 10.00 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast RANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RANI is 10.00 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.570
sliders
Low
9.00
Averages
10.00
High
11.00
Current: 1.570
sliders
Low
9.00
Averages
10.00
High
11.00
H.C. Wainwright
Brandon Folkes
Buy
initiated
$11
2025-10-21
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$11
2025-10-21
initiated
Buy
Reason
H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes the company has "three significant value drivers," its platform technology RaniPill, a recently announced collaboration agreement with Chugai Pharmaceutical for the development of a hemophilia product, and potentially an additional five drug targets, as well as RT-114, an oral GLP-1/GLP-2 dual agonist candidate. It expects data readouts on RT-114 to be the biggest driver of near-term value creation for Rani shares.
Maxim Group
Maxim
Buy
maintain
$5 -> $10
2025-10-20
Reason
Maxim Group
Maxim
Price Target
$5 -> $10
2025-10-20
maintain
Buy
Reason
Maxim raised the firm's price target on Rani Therapeutics to $10 from $5 and keeps a Buy rating on the shares after the company announced a licensing deal with Chugai Pharmaceutical for RaniPill technology and a concurrent private placement to raise $60M in proceeds. The Chugai deal offers both non-dilutive financing as well as "key validation" for RaniPill, the analyst tells investors.
Oppenheimer
Oppenheimer
Outperform
to
NULL
downgrade
$14 -> $4
2025-05-16
Reason
Oppenheimer
Oppenheimer
Price Target
$14 -> $4
2025-05-16
downgrade
Outperform
to
NULL
Reason
Oppenheimer lowered the firm's price target on Rani Therapeutics to $4 from $14 and keeps an Outperform rating on the shares following quarterly and business update. The firm anticipates a mid-2025 initiation of the Phase 1 study for RT-114, an oral RaniPill containing 200microL of ProGen's GLP-1/GLP-2 receptor agonist, PG-102. In March, Rani presented preclinical data demonstrating comparable bioavailability between RT-114 and subcutaneous PG-102 supporting its potential as an effective oral obesity treatment. Oppenheimer views Rani's expansion into obesity as a value-driver, differentiated by tolerability and flexible dosing. Given the company's financial position and advancing RT-114/obesity becoming its prime focus, the firm removes RT-111/psoriasis from its valuation.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$9
2025-04-03
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$9
2025-04-03
Reiterates
Strong Buy
Reason
Canaccord Genuity
Edward Nash
Strong Buy
Maintains
$9
2025-02-26
Reason
Canaccord Genuity
Edward Nash
Price Target
$9
2025-02-26
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$9
2025-02-07
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$9
2025-02-07
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Rani Therapeutics Holdings Inc (RANI.O) is -2.98, compared to its 5-year average forward P/E of -5.51. For a more detailed relative valuation and DCF analysis to assess Rani Therapeutics Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.51
Current PE
-2.98
Overvalued PE
-0.05
Undervalued PE
-10.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.11
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.06
Undervalued EV/EBITDA
-4.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
404.70
Current PS
0.00
Overvalued PS
1206.73
Undervalued PS
-397.34
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 2422.5% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 2422.5% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RANI News & Events

Events Timeline

(ET)
2025-11-06
17:05:57
Rani Therapeutics announces Q3 earnings per share of 12 cents, matching expectations.
select
2025-10-17 (ET)
2025-10-17
07:37:01
Rani Therapeutics reveals conversion of debt into equity
select
2025-10-17
07:36:23
Rani Therapeutics sets price for 42.6 million shares at 48 cents in private placement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-04NASDAQ.COM
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead

  • Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.

  • Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.

  • Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.

  • Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.

[object Object]
Preview
5.0
10-28NASDAQ.COM
Insider Buying Update for Tuesday, October 28: RANI and KO

  • Rani Therapeutics Holdings Insider Purchase: Mir Imran, the CEO of Rani Therapeutics Holdings, bought 2,083,334 shares of RANI for $1.26 million, resulting in a 228.9% gain based on the current trading price.

  • Coca-Cola Insider Purchase: Director Max R. Levchin purchased 14,267 shares of Coca-Cola for $998,676, marking his first purchase in the past year, with Coca-Cola's stock up 0.5% on the same day.

[object Object]
Preview
9.0
10-23NASDAQ.COM
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

  • Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.

  • Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.

  • Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.

  • Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Rani Therapeutics Holdings Inc (RANI) stock price today?

The current price of RANI is 1.57 USD — it has decreased -3.09 % in the last trading day.

arrow icon

What is Rani Therapeutics Holdings Inc (RANI)'s business?

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

arrow icon

What is the price predicton of RANI Stock?

Wall Street analysts forecast RANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RANI is 10.00 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Rani Therapeutics Holdings Inc (RANI)'s revenue for the last quarter?

Rani Therapeutics Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Rani Therapeutics Holdings Inc (RANI)'s earnings per share (EPS) for the last quarter?

Rani Therapeutics Holdings Inc. EPS for the last quarter amounts to -0.12 USD, decreased -50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Rani Therapeutics Holdings Inc (RANI)'s fundamentals?

The market is revising Upward the revenue expectations for Rani Therapeutics Holdings, Inc. (RANI) for FY2025, with the revenue forecasts being adjusted by 2759.98% over the past three months. During the same period, the stock price has changed by 212.62%.
arrow icon

How many employees does Rani Therapeutics Holdings Inc (RANI). have?

Rani Therapeutics Holdings Inc (RANI) has 105 emplpoyees as of December 05 2025.

arrow icon

What is Rani Therapeutics Holdings Inc (RANI) market cap?

Today RANI has the market capitalization of 190.77M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free